Sudeep Pharma Limited has scheduled its 37th Annual General Meeting for Tuesday, August 4, 2026, at 11:00 a.m. via video conferencing. The meeting will seek shareholder approval for a final dividend of ₹1.50 per equity share for FY 2025-26 and the ratification of the Sudeep Pharma Employee Stock Option Scheme 2025. The record date for determining dividend eligibility is fixed as Thursday, July 23, 2026.

Financial Performance

The company's Annual Report for FY 2025-26 disclosed strong consolidated and standalone financial results. On a consolidated basis, revenue from operations reached ₹642.3 Crs, a 28% year-on-year increase from ₹501.99 Crs in FY 2024-25. Profit after tax grew 26% to ₹174.3 Crs with a PAT margin of 27.1%. EBITDA stood at ₹221.9 Crs with an EBITDA margin of 34.6%. Exports contributed 60% of consolidated revenue. The company maintained a conservative debt profile with total borrowings of ₹148.3 Crs and a debt-to-equity ratio of 0.17x.

On a standalone basis, the company reported a profit after tax of ₹10,758.07 lakh for FY 2025-26, compared to ₹9,574.77 lakh in the previous year. Standalone revenue from operations stood at ₹33,850.54 lakh.

Business Segment Performance

The Specialty Ingredients vertical was the fastest-growing segment, with revenue increasing 63% from ₹172 Crs to ₹280 Crs. The Pharmaceutical, Food & Nutrition core vertical contributed around ₹362 Crs, approximately 56% of revenue. For the Battery Materials business under Sudeep Advanced Materials, the company broke ground at Dahej in January 2026. Phase 1 capacity of 25,000 MT is planned for commissioning by April 2027, with around 700 MT of initial commercial orders already received.

AGM Agenda

The AGM will seek shareholder approval to ratify the 'Sudeep Pharma Employee Stock Option Scheme 2025', which covers options not exceeding 21,70,014. Shareholders will also vote on the re-appointment of Mr. Ajay Shrirang Kandelkar as a director and on a revision in his remuneration as Whole Time Director to ₹1,14,97,600 per annum effective from April 1, 2026. The agenda includes the appointment of Mr. Milin Mehta as a Non-Executive, Non-Independent Director. Additionally, the meeting will consider the appointment of Mr. Hemang Mehta as Secretarial Auditor for a term of five years and the ratification of remuneration for Cost Auditors M/s. Chetan Gandhi & Associates.

Sudeep Pharma Ltd appointed Mr. Milin Mehta as an Additional Director in the category of Non-Executive Non-Independent Director effective June 26, 2026. The appointment is subject to the approval of the shareholders of the company. The Board of Directors approved the appointment during its meeting held on June 26, 2026. The director is liable to retire by rotation.

The company confirmed that Mr. Milin Mehta has not been debarred from holding the office of Director by virtue of any SEBI Order or any other Authority. This confirmation was provided in compliance with a SEBI Letter dated June 14, 2018 and a BSE Circular LIST/COMP/14/2018-19 dated June 20, 2018.

Mr. Mehta is the Managing Partner at K C Mehta & Co LLP and has been associated with the firm for over three decades. He is a Chartered Accountant and Law Graduate. He secured a rank in the CA exams and received a Gold Medal in M.Com. from The Maharaja Sayajirao University of Baroda.

Under his leadership, the firm expanded its geographic reach and service capabilities. He established the firm’s International Tax and Transfer Pricing practice and currently leads the Transaction Advisory Services vertical. He continues to guide the Tax and Regulatory practice.

Mr. Mehta has represented clients in complex tax litigation and has contributed to national policy initiatives, including the formulation of the Income Computation and Disclosure Standards (ICDS). He has served as Vice Chairman and Treasurer of the Western India Regional Council of ICAI. He is not related to any Director(s) of the Company as defined under the provisions of Section 2(77) of Companies Act, 2013.

Director Details